Melanoma News and Research

Latest Melanoma News and Research

Fast track approval process for “breakthrough” drugs proposed in the U.S.

Some experimental drugs that show a big effect early in development for treating serious or life-threatening diseases could soon get a faster and cheaper path to U.S. approval, under a proposal likely to become law this year.

10 May 2012

Researchers use clever screening methods to speed vaccine production

Infectious diseases-both old and new-continue to exact a devastating toll, causing some 13 million fatalities per year around the world. Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with co-author Michael McGuire from the University of Texas Southwestern Medical Center are using clever functional screening methods to attempt to speed new vaccines into production that are both safer and more potent.

10 May 2012

NCKU student receives Graduate/Postdoctoral Travel Award from ASBMB

Wan-Pei Su, a graduate student of Molecular Medicine at National Cheng Kung University (NCKU), southern Taiwan, has received a Graduate/Postdoctoral Travel Award from the American Society for Biochemistry and Molecular Biology (ASBMB) to attend the annual conference on Experimental Biology (EB) in San Diego in April 2012.

10 May 2012

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

9 May 2012

More teenagers and young adults diagnosed with skin cancer

With summer just around the corner, pediatricians at Johns Hopkins Children's Center are sounding the alarm on a disturbing trend: A growing number of teenagers and young adults diagnosed with skin cancer.

8 May 2012

Genesis Biopharma terminates previously announced proposed public offering

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, announced today that it is terminating its previously announced proposed public offering pursuant to a preliminary prospectus supplement and an effective shelf registration statement on file with the Securities and Exchange Commission due to market conditions.

8 May 2012

Survey: Many people do not know how to spot skin cancer

Doing a little detective work can go a long way in finding skin cancer, the most common form of cancer diagnosed in the United States, at its earliest, most treatable stage. However, a new survey found that many people do not know how to spot skin cancer and are unaware of their risk of developing the disease.

8 May 2012

iCAD first quarter total revenue decreases 14% to $6.3 million

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the first quarter ended March 31, 2012.

8 May 2012

Eye color linked to high-risk for skin conditions

Eye color may be an indicator of whether a person is high-risk for certain serious skin conditions. A study, led by the University of Colorado School of Medicine, shows people with blue eyes are less likely to have vitiligo.

7 May 2012

iCAD, Breastlink announce agreement to offer Xoft brachytherapy system

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, and Breastlink Medical Group in Southern California, today announced an agreement that will make the Xoft Axxent Electronic Brachytherapy System available to breast cancer patients treated at Breastlink.

5 May 2012

Math models can be useful tools for study of cancer progression

Using mathematical models, researchers in the Integrated Mathematical Oncology (IMO) program at Moffitt Cancer Center are focusing their research on the interaction between the tumor and its microenvironment and the "selective forces" in that microenvironment that play a role in the growth and evolution of cancer.

3 May 2012

MRA, Sports Authority partner in recognition of May's Skin Cancer Awareness Month

Sports Authority, the nation's premier full-line sporting goods retailer, announced today that it has teamed up with the Melanoma Research Alliance (MRA) in recognition of May's Skin Cancer Awareness Month for the second year in a row.

3 May 2012

Topline, interim results from Celldex Phase 2b EMERGE study of CDX-011 for advanced breast cancer

Celldex Therapeutics, Inc. today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study, will join Celldex on the webcast to discuss data from the study.

2 May 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

AlderMed enters distribution agreement with Gulmay Medical for Xstrahl-100 therapy system

AlderMed announced today it has entered into a three-year exclusive distribution agreement with Gulmay Medical, manufacturer of the Xstrahl-100 therapy system.

From Xstrahl 30 Apr 2012

Mount Sinai experts to share skin cancer prevention tips on May 7

Skin cancer is the most common form of cancer in the United States, with one in five Americans developing it over the course of their lives. It's also one of the most preventable types of cancers. Since May is Skin Cancer Awareness Month and Melanoma Monday is May 7, Mount Sinai experts are sharing tips on prevention and insight on the new FDA labeling requirements on sunscreen.

30 Apr 2012

Researchers use Moffitt's Total Cancer Care to create designer lymph nodes

Researchers at Moffitt Cancer Center are in the first phase of creating "designer lymph nodes." Designer lymph nodes are built with specialized gene-modified cells that are injected into patients and produce a pre-planned immunologic response for cancer patients locally and then throughout their bodies. The researchers are examining a cancer vaccine "boosting" effect of the manufactured lymph nodes in patients with advanced melanoma.

30 Apr 2012

A melanoma cloaking protein

Johns Hopkins and Yale scientists have found that melanoma cells use a cloaking protein to hide from immune cells poised to attack the cancer. Nearly 40 percent of their sampling of melanoma tissues contained the B7-H1 protein, also called PD-L1, and scientists say it could be used as a target for new therapies.

26 Apr 2012

Melanomas express B7-H1 protein to hide from T-cells

26 Apr 2012

MMP-10 gene plays a dual role in lung cancer

A single gene that promotes initial development of the most common form of lung cancer and its lethal metastases has been identified by researchers at Mayo Clinic in Florida.

25 Apr 2012